Prospective Assessment of Pituitary Function in Patients with Macroprolactinoma Treated with Cabergoline.

Prospective Assessment of Pituitary Function in Patients with Macroprolactinoma Treated with Cabergoline.

Bibliographic Details
Main Authors:	Karavitaki, N, Wass, J
Format:	Conference item
Published:	2010

Similar Items

Does hypopituitarism recover when macroprolactinomas are treated with cabergoline?
by: Karavitaki, N, et al.
Published: (2013)

Does hypopituitarism recover when macroprolactinomas are treated with cabergoline?
by: Karavitaki, N, et al.
Published: (2013)

The outcome of macroprolactinomas resistant to dopamine agonists
by: Coculescu, M, et al.
Published: (2005)

Efficacy and safety of rapid escalation of cabergoline in comparison to conventional regimen for macroprolactinoma: A prospective, randomized trial
by: Ashu Rastogi, et al.
Published: (2012-01-01)

Clinical Outcome of Invasive Pituitary Prolactinomas Treated with Cabergoline
by: Bassam M Flamerz Arkawazi
Published: (2020-01-01)

Valvular heart disease and the use of cabergoline for the treatment of prolactinoma.
by: Herring, N, et al.
Published: (2009)

A case of macroprolactinoma encasing an internal carotid artery aneurysm, presenting as pituitary apoplexy.
by: Soni, A, et al.
Published: (2008)

Macroprolactinomas and Nonfunctioning Pituitary Adenomas and Pregnancy Outcomes.
by: Lambert, K, et al.
Published: (2017)

Macroprolactinomas and nonfunctioning pituitary adenomas and pregnancy outcomes
by: Lambert, K, et al.
Published: (2017)

Cabergoline-Induced Pneumocephalus Following Treatment for Giant Invasive Macroprolactinoma Presenting With Spontaneous Cerebrospinal Fluid Rhinorrhea
by: Souha S Elabd, et al.
Published: (2018-02-01)

An aggressive cabergoline-resistant, temozolomide-responsive macroprolactinoma due to a germline SDHB pathogenic variant in the absence of paraganglioma or pheochromocytoma
by: Ali S. Alzahrani, et al.
Published: (2023-12-01)

A patient with a germline SDHB mutation presenting with an isolated pituitary macroprolactinoma
by: Michelle Maher, et al.
Published: (2018-07-01)

Can we ever stop imaging in surgically treated and radiotherapy-naive patients with non-functioning pituitary adenoma?
by: Reddy, R, et al.
Published: (2011)

Non-adenomatous pituitary tumours.
by: Karavitaki, N, et al.
Published: (2009)

Diagnosis and management of prolactinomas and non-functioning pituitary adenomas.
by: Rogers, A, et al.
Published: (2014)

Nonfunctioning pituitary adenomas: the Oxford experience.
by: Wass, J, et al.
Published: (2009)

Growth hormone replacement in patients with non-functioning pituitary adenoma treated solely by surgery is not associated with increased risk of tumour recurrence.
by: Arnold, J, et al.
Published: (2008)

GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence.
by: Arnold, JR, et al.
Published: (2009)

The postoperative monitoring of nonfunctioning pituitary adenomas.
by: Wass, J, et al.
Published: (2011)

The postoperative monitoring of nonfunctioning pituitary adenomas
by: Wass, J, et al.
Published: (2011)

Pituitary apoplexy in an adolescent male with macroprolactinoma presenting as middle cerebral artery territory infarction
by: Pankaj Agrawal, et al.
Published: (2022-12-01)

Efficacy of cabergoline therapy in patients with non-functioning pituitary adenomas: A single center clinical experience
by: Guadalupe Vargas-Ortega, et al.
Published: (2022-07-01)

Treatment of pituitary tumors: history.
by: Thanabalasingham, G, et al.
Published: (2005)

Successful Management of a Giant Pituitary Lactosomatotroph Adenoma Only with Cabergoline
by: Emre Bozkirli, et al.
Published: (2013-01-01)

Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma
by: DL Goede, et al.
Published: (2006-04-01)

The modern management of macroprolactinomas.
by: Grossman, A
Published: (1991)

Retrospective assessment of the use of extended-release cabergoline in the management of equine pituitary pars intermedia dysfunction
by: Tania Sundra, et al.
Published: (2024-03-01)

Nonsurgical cerebrospinal fluid rhinorrhea in invasive macroprolactinoma: incidence, radiological, and clinicopathological features.
by: Suliman, S, et al.
Published: (2007)

MANAGEMENT OF ENDOCRINE DISEASE: Pituitary tumour apoplexy.
by: Capatina, C, et al.
Published: (2014)

Reply to Commentary on "Pituitary apoplexy in an adolescent male with macroprolactinoma presenting as middle cerebral artery territory infarction"
by: Pankaj Agrawal, et al.
Published: (2023-03-01)

Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
by: Barber, T, et al.
Published: (2011)

Hydroxychloroquine overcomes cabergoline resistance in a patient with Lactotroph Pituitary neuroendocrine tumor: a case report
by: Shaojian Lin, et al.
Published: (2022-08-01)

Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK).
by: Fernandez, A, et al.
Published: (2010)

Macroprolactinoma in an adolescent female with primary amenorrhoea
by: Ning Zhang, et al.
Published: (2024-12-01)

Pituitary apoplexy in non-functioning pituitary adenomas: Long term follow up is important because of significant numbers of tumour recurrences
by: Pal, A, et al.
Published: (2011)

Pituitary apoplexy in non-functioning pituitary adenomas: long term follow up is important because of significant numbers of tumour recurrences.
by: Pal, A, et al.
Published: (2011)

CABERGOLINE IN PRACTICAL MAMMOLOGY
by: I. V. Vysotskaya, et al.
Published: (2016-12-01)

Cabergoline or bromocriptine for prolactinoma?
by: Nicolás Triantafilo, et al.
Published: (2016-09-01)

Macroprolactinoma resistente aos agonistas dopaminérgicos: relato de caso Macroprolactinoma resistant to dopamine agonists: a case report
by: Rosana Maria dos Reis, et al.
Published: (2004-09-01)

Thyrotropin-secreting pituitary tumor presenting with congestive heart failure and good response to dopaminergic agonist cabergoline
by: Yu-Hsi Kao, et al.
Published: (2013-11-01)